SCHEMBL2887030

SCHEMBL2887030

COc1ccc(C(=O)c2ccc(C3=NC4CCCCC4c4cc(OC)c(OC)cc43)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 6/20 0.49
PDE4B Q07343 5/20 0.49
PDE4A P27815 4/20 0.49
PDE4C Q08493 4/20 0.49
ALDH1A1 P00352 3/20 0.44
GAA P10253 1/20 0.44
LMNA P02545 1/20 0.41
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41
TUBA4A P68366 1/20 0.41
TUBB4B P68371 1/20 0.41
TUBB3 Q13509 1/20 0.41
TUBB2A Q13885 1/20 0.41
TUBB8 Q3ZCM7 1/20 0.41
TUBA3E Q6PEY2 1/20 0.41
TUBA1A Q71U36 1/20 0.41
TUBA1C Q9BQE3 1/20 0.41
TUBB6 Q9BUF5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2887024 1.00 PDE4D (0.49) PDE4DPDE4BPDE4APDE4CALDH1A1
SCHEMBL2887026 1.00 PDE4D (0.49) PDE4DPDE4BPDE4APDE4CALDH1A1
SCHEMBL2887949 0.92 PDE4B (0.49) PDE4DPDE4BPDE4APDE4CHPGD
SCHEMBL2887953 0.92 PDE4B (0.49) PDE4DPDE4BPDE4APDE4CHPGD
SCHEMBL2887955 0.92 PDE4B (0.49) PDE4DPDE4BPDE4APDE4CHPGD
SCHEMBL2886315 0.91 PDE4D (0.46) PDE4DPDE4BPDE4APDE4CALDH1A1
SCHEMBL2886314 0.91 PDE4D (0.46) PDE4DPDE4BPDE4APDE4CALDH1A1
SCHEMBL2886311 0.91 PDE4D (0.46) PDE4DPDE4BPDE4APDE4CALDH1A1
SCHEMBL2883553 0.91 PDE4B (0.48) PDE4DPDE4BPDE4APDE4CLMNA
SCHEMBL2886712 0.91 PDE4B (0.48) PDE4DPDE4BPDE4APDE4CLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005023253-A1 USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS ALTANA PHARMA AG (DE) 2005-03-17 WO claimed
US-7776893-B2 Use of PDE4 inhibitors for the treatment of diabetes mellitus NYCOMED GMBH (DE) 2010-08-17 US disclosed
US-20060281745-A1 Use of pde4 inhibitors for the treatment of diabetes mellitus ALTANA PHARMA AG (DE) 2006-12-14 US disclosed
EP-1650193-A2 6-Phenylphenanthridines with PDE-IV inhibiting activity ALTANA Pharma AG (DE) 2006-04-26 EP disclosed
EP-1147089-B1 PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY ALTANA PHARMA AG (DE) 2005-12-07 EP disclosed
US-6476025-B1 Phenylphennanthridines with PDE-IV inhibiting activity ALTANA PHARMA AG (DE) 2002-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281745-A1 Use of pde4 inhibitors for the treatment of diabetes mellitus PDE4A, PDE4B, PDE12 PDE4D 4/4885PDE4B 2/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.